What is MOKSHA8 PHARMACEUTICALS?
Founded in 2007 and headquartered in Berwyn, PA, MOKSHA8 PHARMACEUTICALS is a pharmaceutical company with a strong presence in Latin America. The company's core mission revolves around the commercialization of high-quality medicines, supported by best-in-class operations and a commitment to FCPA compliance. MOKSHA8 launched its commercial operations in 2008, initially focusing on CNS products in Brazil and Mexico. The company has established a broad alliance with Forest Laboratories across Latin America and maintains partnerships with other key industry players such as GSK, Sandoz, Aurobindo, and Accord in Brazil. The company was co-founded by Simba Gill and TPG Biotechnology.
How much funding has MOKSHA8 PHARMACEUTICALS raised?
MOKSHA8 PHARMACEUTICALS has raised a total of $219.1M across 4 funding rounds:
Series A
$39M
Series B
$25.1M
Series C
$30M
Unspecified
$125M
Series A (2008): $39M with participation from TPG Biotech
Series B (2009): $25.1M led by Montreux Equity Partners
Series C (2010): $30M supported by Watson
Unspecified (2012): $125M featuring Forest Laboratories
Key Investors in MOKSHA8 PHARMACEUTICALS
Montreux Equity Partners
Montreux Equity Partners is a venture capital firm that typically invests in companies with proven business models and significant growth potential, often focusing on the healthcare and technology sectors.
TPG Biotech
TPG Biotech is an investment firm specializing in the life sciences sector, providing capital and strategic support to companies across biotechnology, pharmaceuticals, and medical devices.
Forest Laboratories
Forest Laboratories, prior to its acquisition, was a pharmaceutical company known for licensing and commercializing medicines, particularly in the CNS space, and had established significant alliances in Latin America.
What's next for MOKSHA8 PHARMACEUTICALS?
The recent major strategic investment in MOKSHA8 PHARMACEUTICALS signals a pivotal phase for the company, likely aimed at accelerating its commercialization efforts, expanding its product portfolio, or entering new geographic markets within Latin America. Given its history of enterprise-level funding, this capital injection is expected to bolster its operational capabilities and strengthen its market penetration. The company's strategic alliances and partnerships provide a robust foundation for future growth, suggesting a trajectory focused on consolidating its position as a leading pharmaceutical provider in its target regions.
See full MOKSHA8 PHARMACEUTICALS company page
